Patients with advanced or refractory/relapsing ALCL, BI-ALCL or CALCL obtain their first benefit from targeted therapies directed against CD30, ALK, NOTCH1 or JAK (Table 1 and Table 2). Here, NOTCH1 is linked to anaplastic large cell lymphoma.